From: Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis
Parameters | All patients (n = 39) | Patients with positive DAT (n = 17) | Patients with negative DAT (n = 22) | p |
---|---|---|---|---|
Age, median (IQR) | 44 (24.5–51.5) | 49.5 (43.2–54.7) | 31 (20.5–48) | 0.01 |
Female sex, number of patients (%) | 13/39 (33.3%) | 4/17 (23.5%) | 9/22 (40.9%) | 0.3 |
Born in malaria endemic countries, number of patients (%) | 4/26 (15.4%) | 1/10 (10%) | 3/16 (18.7%) | 1 |
Resident in malaria endemic countries, number of patients (%) | 7/28 (25%) | 2/11 (18.2%) | 5/17 (29.4%) | 0.7 |
P. falciparum, number of patients (%) | 35/39 (89.7%) | 15/17 (88.2%) | 20/22 (90.9%) | 1 |
P. falciparum + P. vivax, number of patients (%) | 3/39 (7.7%) | 2/17 (11.8%) | 1/22 (4.5%) | 0.6 |
P. vivax, number of patients (%) | 1/39 (2.6%) | 0/17 (0) | 1/22 (4.5%) | 1 |
Parasitaemia, median (IQR) | 20.8% (11.2–30) | 27% (21–34) | 17% (9–22) | 0.03 |
Hyperparasitaemia (> 10%), number of patients (%) | 28/36 (77.8%) | 14/17 (82.3%) | 14/19 (73.7%) | 0.7 |
Number of WHO severe malaria criteria [2], median (IQR) | 3 (2–3) | 3 (2–4) | 3 (2–3) | 0.6 |
Patients with acute kidney injury, number of patients (%) | 16/35 (45.7%) | 10/16 (62.5%) | 6/19 (31.6%) | 0.09 |
Parasite clearance time in days, median (IQR) | 3 (2–4) | 4 (3–5.5) | 3 (2–4) | 0.3 |
Intravenous artesunate, number of patients (%) | 32/39 (82%) | 15/17 (88.2%) | 17/22 (77.3%) | 0.4 |
Intrarectal artesunate, number of patients (%) | 2/39 (5.1%) | 1/17 (5.9%) | 1/22 (4.5%) | 1 |
Artesunate + oral ACT, number of patients (%) | 17/37 (45.9%) | 7/15 (46.7%) | 10/22 (45.4%) | 1 |
Not receiving artesunate (only other artemisinines), number of patients (%) | 5/39 (12.8%) | 1/17 (5.9%) | 4/22 (18.2%) | 0.4 |
Oral quinine, number of patients (%) | 10/37 (27%) | 6/15 (40%) | 4/22 (18.2%) | 0.3 |
Oral doxycycline, number of patients (%) | 10/37 (27%) | 5/15 (33.3%) | 5/22 (22.7%) | 0.7 |
Oral clindamycin, number of patients (%) | 4/37 (10.8%) | 0/15 (0) | 4/22 (18.2%) | 0.1 |
Days of intravenous Artesunate therapy, median (IQR) | 3 (2–4) | 3 (2–3.7) | 3 (2.7–4) | 0.8 |
Basal haemoglobin (Hb), median (IQR) | 12.4 (10.7–13.8) | 12.5 (11.2–13.2) | 11.8 (10.5–14.3) | 0.8 |
Time to PADH onset, in days, median (IQR) | 12 (8.5–14) | 13 (8.2–14) | 11 (9–13) | 0.5 |
Time to Hb Nadir during PADH, in days, median (IQR) | 14 (11–15) | 14.5 (12.2–16.7) | 13 (11.2–15) | 0.3 |
Hb level at nadir, median (IQR) | 6 (5.2–6.8) | 6.5 (5.4–6.9) | 5.9 (4.8–6.4) | 0.2 |
IgG DAT, number of patients (%) | – | 5/13 (38.5%) | – | – |
C3d DAT, number of patients (%) | – | 6/13 (46.1%) | – | – |
IgG/C3d DAT, number of patients (%) | – | 2/13 (15.4%) | – | – |
Patients treated with systemic corticosteroids, number of patients (%) | 14/37 (37.8%) | 11/16 (68.7%) | 3/21 (14.3%) | 0.002 |
Patients receiving transfusions, number of patients (%) | 29/39 (74.4%) | 12/17 (70.6%) | 17/22 (77.3%) | 0.7 |
Number of red blood cells units transfused, median (IQR) | 2 (0–4) | 2 (0–4) | 3.5 (0–4) | 0.5 |